269 related articles for article (PubMed ID: 19361546)
21. Anti-PEG IgM Production via a PEGylated Nanocarrier System for Nucleic Acid Delivery.
Abu Lila AS; Ishida T
Methods Mol Biol; 2019; 1943():333-346. PubMed ID: 30838627
[TBL] [Abstract][Full Text] [Related]
22. Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells.
Shimizu T; Mima Y; Hashimoto Y; Ukawa M; Ando H; Kiwada H; Ishida T
Immunobiology; 2015 Oct; 220(10):1151-60. PubMed ID: 26095176
[TBL] [Abstract][Full Text] [Related]
23. Peritoneal B Cells Play a Role in the Production of Anti-polyethylene Glycol (PEG) IgM against Intravenously Injected siRNA-PEGylated Liposome Complexes.
Shimizu T; Lila ASA; Kitayama Y; Abe R; Takata H; Ando H; Ishima Y; Ishida T
Biol Pharm Bull; 2024; 47(2):469-477. PubMed ID: 38383000
[TBL] [Abstract][Full Text] [Related]
24. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
[TBL] [Abstract][Full Text] [Related]
25. Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice.
Hashimoto Y; Shimizu T; Abu Lila AS; Ishida T; Kiwada H
Biol Pharm Bull; 2015; 38(3):417-24. PubMed ID: 25757923
[TBL] [Abstract][Full Text] [Related]
26. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
27. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.
Abu Lila AS; Eldin NE; Ichihara M; Ishida T; Kiwada H
Int J Pharm; 2012 Nov; 438(1-2):176-83. PubMed ID: 22944302
[TBL] [Abstract][Full Text] [Related]
28. Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery.
Tagami T; Suzuki T; Matsunaga M; Nakamura K; Moriyoshi N; Ishida T; Kiwada H
Int J Pharm; 2012 Jan; 422(1-2):280-9. PubMed ID: 22101286
[TBL] [Abstract][Full Text] [Related]
29. Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats.
Wang XY; Ishida T; Ichihara M; Kiwada H
J Control Release; 2005 May; 104(1):91-102. PubMed ID: 15866337
[TBL] [Abstract][Full Text] [Related]
30. Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes.
Sonoke S; Ueda T; Fujiwara K; Sato Y; Takagaki K; Hirabayashi K; Ohgi T; Yano J
Cancer Res; 2008 Nov; 68(21):8843-51. PubMed ID: 18974128
[TBL] [Abstract][Full Text] [Related]
31. Zwitterionic poly(carboxybetaine)-based cationic liposomes for effective delivery of small interfering RNA therapeutics without accelerated blood clearance phenomenon.
Li Y; Liu R; Shi Y; Zhang Z; Zhang X
Theranostics; 2015; 5(6):583-96. PubMed ID: 25825598
[TBL] [Abstract][Full Text] [Related]
32. Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: Appearance of an unexplained mechanism in the ABC phenomenon.
El Sayed MM; Takata H; Shimizu T; Kawaguchi Y; Abu Lila AS; Elsadek NE; Alaaeldin E; Ishima Y; Ando H; Kamal A; Sarhan HA; Ishida T
J Control Release; 2020 Jul; 323():102-109. PubMed ID: 32278827
[TBL] [Abstract][Full Text] [Related]
33. PEG-detachable cationic polyaspartamide derivatives bearing stearoyl moieties for systemic siRNA delivery toward subcutaneous BxPC3 pancreatic tumor.
Kim HJ; Oba M; Pittella F; Nomoto T; Cabral H; Matsumoto Y; Miyata K; Nishiyama N; Kataoka K
J Drug Target; 2012 Jan; 20(1):33-42. PubMed ID: 22066783
[TBL] [Abstract][Full Text] [Related]
34. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
Malek A; Merkel O; Fink L; Czubayko F; Kissel T; Aigner A
Toxicol Appl Pharmacol; 2009 Apr; 236(1):97-108. PubMed ID: 19371615
[TBL] [Abstract][Full Text] [Related]
35. Ultrasound assisted siRNA delivery using PEG-siPlex loaded microbubbles.
Vandenbroucke RE; Lentacker I; Demeester J; De Smedt SC; Sanders NN
J Control Release; 2008 Mar; 126(3):265-73. PubMed ID: 18237813
[TBL] [Abstract][Full Text] [Related]
36. Grafting of poly(ethylene glycol) to poly-lysine augments its lifetime in blood circulation and accumulation in tumors without loss of the ability to associate with siRNA.
Kano A; Moriyama K; Yamano T; Nakamura I; Shimada N; Maruyama A
J Control Release; 2011 Jan; 149(1):2-7. PubMed ID: 20005270
[TBL] [Abstract][Full Text] [Related]
37. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
Abu Lila AS; Kizuki S; Doi Y; Suzuki T; Ishida T; Kiwada H
J Control Release; 2009 Jul; 137(1):8-14. PubMed ID: 19285528
[TBL] [Abstract][Full Text] [Related]
38. TLR9-dependent systemic interferon-beta production by intravenous injection of plasmid DNA/cationic liposome complex in mice.
Yoshida H; Nishikawa M; Yasuda S; Mizuno Y; Toyota H; Kiyota T; Takahashi R; Takakura Y
J Gene Med; 2009 Aug; 11(8):708-17. PubMed ID: 19462411
[TBL] [Abstract][Full Text] [Related]
39. Ganglioside inserted into PEGylated liposome attenuates anti-PEG immunity.
Mima Y; Abu Lila AS; Shimizu T; Ukawa M; Ando H; Kurata Y; Ishida T
J Control Release; 2017 Mar; 250():20-26. PubMed ID: 28179196
[TBL] [Abstract][Full Text] [Related]
40. Size-dependent induction of accelerated blood clearance phenomenon by repeated injections of polymeric micelles.
Koide H; Asai T; Kato H; Ando H; Shiraishi K; Yokoyama M; Oku N
Int J Pharm; 2012 Aug; 432(1-2):75-9. PubMed ID: 22562054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
